The global fragment-based drug discovery market was valued at USD 868.42 million in 2023 and is projected to grow to USD 954.32 million in 2024, eventually reaching USD 2,313.43 million by 2032. This growth represents a robust compound annual growth rate (CAGR) of 11.5% during the forecast period (2024–2032).
Market Definition and Key Insights:Fragment-based drug discovery (FBDD) involves identifying small chemical fragments that bind to biological targets and optimizing these fragments into potent drug candidates. FBDD has become a vital tool in modern drug discovery due to its efficiency in generating leads for complex and traditionally undruggable targets.
Latest Market Trends:
Advancements in Screening Techniques: Innovations in fragment screening technologies such as nuclear magnetic resonance (NMR) spectroscopy and X-ray crystallography have enhanced the precision and speed of drug discovery processes.
AI Integration: Artificial intelligence is being increasingly leveraged to predict fragment binding and optimize lead compounds, reducing costs and time in the drug development pipeline.
Rising Focus on Undruggable Targets: Pharmaceutical companies are investing in fragment-based approaches to target protein-protein interactions and other challenging biological mechanisms.
Get a Full PDF Sample Copy of the Report: https://straitsresearch.com/report/fragment-based-drug-discovery-market/request-sample
Key Market Drivers:
Increasing prevalence of chronic diseases such as cancer, cardiovascular conditions, and CNS disorders, necessitating the development of new therapeutic approaches.
The growing adoption of fragment-based techniques over traditional high-throughput screening methods due to their cost-effectiveness and higher success rates.
Key Market Opportunities:
Expansion into emerging markets in Asia-Pacific, driven by rising healthcare investments and the establishment of biopharmaceutical research facilities.
Collaborations between academic institutions and industry players to drive innovation in fragment-based methodologies.
Enhanced focus on personalized medicine, which aligns with the precise targeting capabilities of FBDD.
Market Segmentation:The fragment-based drug discovery market is segmented as follows:
By Service Components:
Fragment Screening:• Biophysical Techniques:
NMR Spectroscopy
DSF Assay
Fluorescence Polarization (FP)
Isothermal Titration Calorimetry (ITC)
X-ray Crystallography
Surface Plasmon Resonance
Mass Spectrometry
Capillary Electrophoresis
Other Biophysical Techniques• Non-Biophysical Techniques
Fragment Optimization
By End-User:
Biopharmaceutical Companies
Contract Research Organizations (CROs)
Academic and Research Institutions
By Applications:
Oncology
Central Nervous System (CNS) Disorders
Infectious Diseases
Cardiovascular Diseases
Metabolic Disorders
Inflammation and Autoimmune Diseases
Access Detailed Segmentation: https://straitsresearch.com/report/fragment-based-drug-discovery-market/segmentation
List of Key Players:
Pfizer Inc.
Novartis AG
Johnson & Johnson
Alveus Pharmaceuticals Pvt. Ltd.
Astex Pharmaceuticals
Charles River Laboratories International, Inc.
Beactica AB
Emerald BioStructures, Inc.
Crown Bioscience, Inc.
Evotec AG
Proteros Fragments GmbH
Kinetic Discovery Limited
Sprint Bioscience
Sygnature Discovery
Structure Based Design, Inc.
Regional Insights:
Dominated Region: North America remains the market leader due to its strong biopharmaceutical industry and research capabilities.
Fastest Growing Region: Asia-Pacific is projected to witness rapid growth, fueled by increasing investments in healthcare infrastructure and drug discovery initiatives.
For More Information or Query or Customization Before Buying: https://straitsresearch.com/buy-now/fragment-based-drug-discovery-market
About Straits Research:Straits Research is a leading market intelligence firm offering in-depth insights into diverse industries. With a focus on delivering actionable intelligence, Straits Research supports decision-making for global businesses.
Comments